Site Map

Universitätsmedizin Mainz



Registration required!!!

Please register **until 19th of September 2024** at https://survey.zdv.uni-mainz.de/index.php/426635?lang=en



Organisation Dr. Ann-Kathrin Herrmann Scientific Coordinator UCT Mainz Phone: +49 (0) 6131 - 175487 Email: uct-science@unimedizin-mainz.de



The UCT Mainz presents

6th Mini-Symposium in Translational Oncology (MiTraC)

Targeting Cancer – Novel Mechanisms and Opportunities

26th of September 2024 | 1.00 - 6.00 pm

Lecture Hall Building 401



uct Universitäres Centrum für Tumorerkrankungen MAINZ

The UCT Mainz presents

6th Mini-Symposium in **Translational Oncology** (MiTraC)

Dear friends & colleagues,

we are happy to welcome you to the 6th UCT Mainz Mini-Symposium in Translational Oncology (MiTraC) sponsored by Merck Healthcare KGaA.

In this Mini-Symposium series we aim to address important areas of cancer research linked to translational oncology. Within this format, we have the opportunity to invite outstanding scientists to present novel findings, techniques and ideas.

The topic of this year's symposium is "Targeting Cancer -Novel Mechanisms and Opportunities", which covers two prominent scientific core areas of the UCT Mainz. The talks will address major topics of many research groups working at the UCT Mainz and our partnering institutions and clinics.

We wish you a pleasant time and an interesting symposium with lots of new insights and discoveries!

With best regards,

Thomas Kindler

Ann-Kathrin Herrmann Head of the UCT Mainz Scientific Coordinator UCT Mainz

Sponsored by





uct | Universitäres Centrum für Tumorerkrankungen MAINZ

Program

13.00 Uhr Welcome

Thomas Kindler, UCT Mainz Gina Walter-Bausch, Merck Healthcare KGaA

Session 1: Successful Immunotherapy: T cells, D cells and the gut Astrid Alflen Chair:

13.05 Uhr Coordination of anti-cancer T cell immunity by intratumoral dendritic cells Jan Böttcher, Munich

13.45 Uhr Dissection of successful tumor-infiltrating lymphocyte immunotherapy Andrew K. Sewell, Cardiff

14.25 Uhr Decoding host-microbiome interactions in cancer immunity. Killing cancer with a gut instinct Evangelos Giampazolias, Manchester

15.05 Uhr Coffee Break & Networking

Session 2: Targeting DNA damage repair to treat cancer Hakim Echchannaoui Chair:

15.55 Uhr Mechanisms for PARP inhibitor efficacy and toxicity Thanos D. Halazonetis, Geneva

16.35 Uhr Finding new drug targets: CRISPR/ **Cas9 KO screens for systematic** identification of synthetic lethal interactions in DNA repair Özdemirhan Sercin, Heidelberg

17.15 Uhr Selective targeting of PARP1 in subgroups of biliary tract cancers Darko Castven, Lübeck

17.55 Uhr Closing Remarks & Summary